Strategic MAnagement to Optimize Response To Cardiac Resynchronization Therapy
- Conditions
- Heart Failure, Ventricular Tachycardia, Ventricular Fibrillation
- Registration Number
- JPRN-UMIN000033176
- Lead Sponsor
- Boston Scientific Corporation Rhythm Management
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 726
Not provided
Subjects with documented permanent complete AV block Subjects with permanent or chronic atrial fibrillation (AF) or in AF at the time of enrollment Subjects who have previously received cardiac resynchronization therapy with pacing in the left ventricle Subjects on the active heart transplant list or who has or is to receive ventricular assist device (VAD) Life expectancy shorter than 12 months due to any medical condition (e.g., cancer, uremia, liver failure, etc) Subject with a known or suspected sensitivity to dexamethasone acetate (DXA) Subject is enrolled in any other concurrent clinical study, with the exception of local mandatory governmental registries and observational studies/registries, without the written approval from Boston Scientific Women of childbearing potential who are or plan to become pregnant during the course of the trial Subjects currently requiring dialysis
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method